

Seoul, Korea: 26-29 April 2016

Complex PCI: Left Main & Bifurcation

Are all DES equal
for LM stenting?

Speaker - 10'

Antonio Colombo

*Centro Cuore Columbus and
S. Raffaele Scientific Institute, Milan, Italy*

No conflicts to disclose

- Longitudinal links maintain longitudinal integrity of the stent when an external force is applied*




**Longitudinal
Deformation**

The higher the deformation, the weaker is the stent resistance to longitudinal deformation

>4 longitudinal connecting links	2/3 longitudinal connecting points	2 longitudinal connecting links
---	--	---

Cre8 results vs other DES




Less Deform

More Deform


GOOD

BAD

Recoil 1 minute post deployment (%)



Resistance of Stent fracture



Trial	Stent type	Patients	Follow-up time	Composite Endpoint	Stent thrombosis	Repeat revascularisations	TVR	TLR
Randomised Trials								
LE MANS	DES (35%) / BMS (65%)	52	10 years	Death, MI, TVR, stroke	51.1%	-	26.1%	
SYNTAX	Taxus	357	5 years	Death, MI, repeat revasc, stroke	36.9%	5.1%	26.7%	
PRECOMBAT	Cypher	300	5 years	Death, MI, stroke, I- TVR	17.5%	0.3%	13.0%	12.4%
PRECOMBAT - 2	Xience V	334	1.5 years	Death, MI, I- TVR, stroke	8.9%	0.0%		6.5% (I- TVR)
ISAR LEFT MAIN	Taxus	302	2 years	Death, MI, TLR	21.3%	0.3%		9.2%
	Cypher	305	2 years		20.6%	0.7%		10.7%
ISAR LEFT MAIN 2	Resolute	324	1 year	Death, MI, TLR	17.5%	0.9%		11.7%
	Xience	326	1 year		14.3%	0.6%		9.4%
Registries								
EXCELLENT	Xience V	160	1 year	Death, MI, I- TVR	7.5%	0.6%		2.5% (I- TVR) 2.5% (I- TLR)
	Cypher	115	1 year		13.9%	1.7%		7% (I- TVR) 7% (I- TLR)
DELTA	Cypher (938), Taxus (893), Resolute (4), Xience V (43)	1874	3.55 years	Death, stroke, MI, TVR	34.9%	1.7%	15.5%	10.2%
ASAN-MAIN	BMS	100	10 years	Death, Q-wave MI, stroke	25.2%	-	43.1%	36.7% 24.9%
	Cypher (95.5%); Taxus (4.5%)	176	5 years		10.0%	1.8%	19.7%	16.2% 13.2%
ULMD Florence	Taxus	224	1 year	Death, MI, TVR, stroke	20.4%	4.2%		13.8%
	Xience V, Promus	166	1 year		10.2%	1.8%		4.2%

Randomised Trials	Stent type	Patient s	Follow-up time	Composite Endpoint		Stent thrombosis	Repeat revascularisation	TVR	TLR
LE MANS	DES (35%) / BMS (65%)	52	10 years	Death, MI, TVR, stroke	51.1%	-	26.1%		
SYNTAX	Taxus	357	5 years	Death, MI, repeat revasc, stroke	36.9%	5.1%	26.7%		
PRECOMBAT	Cypher	300	5 years	Death, MI, stroke, I-TVR	17.5%	0.3%	13.0%	12.4%	
PRECOMBAT - 2	Xience V	334	1.5 years	Death, MI, I-TVR, stroke	8.9%	0.0%		6.5% (I-TVR)	
ISAR LEFT MAIN	Taxus	302	2 years	Death, MI, TLR	21.3%	0.3%			9.2%
	Cypher	305	2 years		20.6%	0.7%			10.7%
ISAR LEFT MAIN 2	Resolute	324	1 year	Death, MI, TLR	17.5%	0.9%			11.7%
	Xience	326	1 year		14.3%	0.6%			9.4%


Registries	Stent type	Patients	Follow-up time	Composite Endpoint		Stent thrombosis	Repeat revascularisation	TVR	TLR
EXCELLEN T	Xience V	160	1 year	Death, MI, I-TVR	7.5%	0.6%		2.5% (I-TVR)	2.5% (I-TLR)
	Cypher	115	1 year		13.9%	1.7%		7% (I-TVR)	7% (I-TLR)
DELTA	Cypher (938), Taxus (893), Resolute (4), Xience V (43)	1874	3.55 years	Death, stroke, MI, TVR	34.9%	1.7%		15.5%	10.2%
ASAN-MAIN	BMS	100	10 years	Death, Q-wave MI, stroke	25.2%	-	43.1%	36.7%	24.9%
	Cypher (95.5%); Taxus (4.5%)	176	5 years		10.0%	1.8%	19.7%	16.2%	13.2%
ULMD Florence	Taxus	224	1 year	Death, MI, TVR, stroke	20.4%	4.2%		13.8%	
	Xience V, Promus	166	1 year		10.2%	1.8%		4.2%	
MAIN-COMPARE	BMS / 1st gen DES	1102	5 years	Death, Q-wave MI, stroke	12.2%	1.5% (DES)		16.0%	

Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease


3-Year Results of PRECOMBAT-2 Study

PRECOMBAT-2 Study Compared with PRECOMBAT RCT

MACCE: Death, MI, Stroke or Ischemic TVR




3-Y MACCE in LM Subgroups



Adjusted Hazard Ratios *of MACCE* Between CABG and PCI

P for Interaction = 0.002



Conclusions: PRECOMBAT 2 Registry

- PCI with Xience V stent showed feasible 3-year outcomes compared with the historical control of PRECOMBAT study.
- The 3-year incidences of death, MI or stroke were comparable between Xience V and historical controls of PRECOMBAT Cypher and CABG.
- The incidence of MACCE and its individual end points of death, MI, stroke or ischemia-driven TVR were similar between Xience V and Cypher stents.
- The efficacy of new-generation Xience V DES will be clearly identified in the ongoing EXCEL RCT trial.